After announcing a $100 million Series B+ funding, the biotech company’s CEO tells FinanceAsia it is now in full IPO preparation mode with Hong Kong as its preferred destination. However, a dual listing is not out of the question.
Delisting stock and privatising is a big undertaking, but Chinese companies are increasingly using this method to both restructure and recapitalise their businesses. With the right financial partner, it can be a great opportunity to revitalise your brand.
The builder of one of China’s tallest buildings has sold a $700 million bond – the largest for a first-time borrower in the sub-investment grade space – underscoring strong appetite for deal structures with extra investor protection.